Original post on ABC7 News ROCKVILLE, Md. (7News) — There’s more good news in the fight to cure HIV. American Gene Technologies says its clinical trial has resulted in more patients with substantial increases in virus-specific T-cells with immunity against HIV. Progress in HIV cure: AGT hopes to have a ‘functionally cured patient… [Read More]
American Gene Technologies Applauds the State of Maryland for Supporting Biotech Investment
Maryland’s Biotechnology Investment Incentive Tax Credit (BIITC) program generates multiple benefits for the state American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, thanks the State of Maryland for its commitment to supporting biotech research through initiatives like the Biotechnology Investment Incentive Tax Credit (BIITC) program. While AGT is no longer eligible… [Read More]
American Gene Technologies Advances Closer to Demonstrating a Potential Cure for HIV
HIV cure clinical trial data shows safety and efficacy of AGT’s gene therapy treatment, the company will begin withdrawing participants from antiretrovirals in Q2 to test potential functional cure American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that the independent Institutional Review Board (IRB) overseeing its clinical trial approved the… [Read More]
American Gene Technologies’ HIV Clinical Trial Demonstrates Blood Markers of Efficacy
Data from the First Three Patients Shows Critical Markers of the HIV Cure Cell Therapy: Engraftment, Persistence, and Function of Infused Cells American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that it has reached two important milestones for its HIV cure program. All three patients achieved engraftment of the genetically… [Read More]
American Gene Technologies Passes Major Milestone in Potential HIV Cure Clinical Trial with Third Patient Showing No Serious Adverse Effects (SAEs)
American Gene Technologies (AGT), a clinical-stage biotechnology company, announced that the independent Data Safety and Monitoring Board (DSMB) overseeing the trial of AGT’s HIV gene therapy found no serious adverse events (SAEs) from the treatment for the third patient and voted unanimously to allow AGT’s HIV cure program to continue at a faster pace, eliminating the requirement… [Read More]
One Zero: “The Gene Fix That Could Cure HIV”
Published by: One Zero Written by: Emily Mullin Antiretroviral drugs make HIV manageable, but gene therapies could eliminate the virus altogether — provided the treatments can be made safe and economical In the mid-1990s, scientists made a curious but remarkable discovery: A man named Stephen Crohn seemed virtually immune to HIV. In the years before that discovery,… [Read More]
Montgomery Magazine: “Jeffrey Galvin’s BioTech Firm May Be on The Verge of Curing HIV/AIDS”
Published by: Montgomery Magazine | Issue: August – September 2019, Page 42 Written by: Jeff Thoreson | Photograph by: Kevin Allen A 3D RENDERING OF HIV VIRUS IN BLOOD STREAM Jeffrey Galvin has been a computer nerd since the seventh grade. Way back in the 1970s era of mainframes, he became interested not so much… [Read More]
HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV
ROCKVILLE, Md. — American Gene Technologies (AGT), a leading gene and cell therapy company based in Rockville, MD, selected the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) as a new clinical site for its non-IND study, AGT-CS168, to collect clinical specimens from HIV positive individuals. AGT will use… [Read More]
C&EN: “With Several Long-acting HIV Treatments In The Works, The Newest Drugs Emphasize Convenience”
Published by: C&EN on May 12, 2019, In Volume 97, Issue 19. Written by: Megha Satyanarayana Lionel Hillard’s boss asked him to come into his office. It was the late 1980s in Dallas. The then 29-year-old was a medical assistant at a busy clinic with a room full of patients. But the doctor who ran… [Read More]
HIV Cure Program Patent Granted To American Gene Technologies
ROCKVILLE, Md., May 21, 2019 (GLOBE NEWSWIRE) — American Gene Technologies, a leading gene and cell therapy company based in Rockville, Md., was granted a second patent for its unique molecule, methods, and cell process for its HIV program. This patent further protects AGT’s lentiviral vector and proprietary process for generating autologous cell products to treat HIV… [Read More]
Second Patient Cured of HIV and The Implications for American Gene Technologies’s AGT103-T
ROCKVILLE, MD, UNITED STATES, March 8, 2019 / American Gene Technologies (AGT) is pleased to see the release of information about a second individual cured of HIV in London–recently reported in the Wall Street Journal and New York Times. The patient was treated with a bone marrow transplant from a CCR5-Δ32 donor. The London Patient… [Read More]
American Gene Technologies Signs Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy
AGT signed Research Collaboration Agreement with National Institute of Allergy and Infectious Diseases for studies on AGT’s cell and gene therapy for HIV/AIDS. ROCKVILLE, MD, UNITED STATES, February 14, 2019 /EINPresswire.com/ — American Gene Technologies (AGT) recently signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the… [Read More]
